Other formats:
BibTeX
LaTeX
RIS
@article{1390003,
author = {Fojtů, Michaela and Gumulec, Jaromír and Stračina, Tibor and Raudenská, Martina and Skotáková, Anna and Vaculovičová, Markéta and Adam, Vojtech and Babula, Petr and Nováková, Marie and Masařík, Michal},
article_location = {Sharjah},
article_number = {3},
doi = {http://dx.doi.org/10.2174/1389200218666170105165444},
keywords = {Doxorubicin; nanoparticles; liposomal; polymeric; protein; gold; cardiotoxicity; nanocarriers},
language = {eng},
issn = {1389-2002},
journal = {Current Drug Metabolism},
title = {Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review},
volume = {18},
year = {2017}
}
TY - JOUR
ID - 1390003
AU - Fojtů, Michaela - Gumulec, Jaromír - Stračina, Tibor - Raudenská, Martina - Skotáková, Anna - Vaculovičová, Markéta - Adam, Vojtech - Babula, Petr - Nováková, Marie - Masařík, Michal
PY - 2017
TI - Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
JF - Current Drug Metabolism
VL - 18
IS - 3
SP - 237-263
EP - 237-263
PB - Bentham Science Publishers B.V.
SN - 13892002
KW - Doxorubicin
KW - nanoparticles
KW - liposomal
KW - polymeric
KW - protein
KW - gold
KW - cardiotoxicity
KW - nanocarriers
N2 - Background: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by co-administration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet. Objective: This review represents an overall appraisal of studies concerning with the utilization of various doxorubicin-loaded nanoparticles in the cancer treatment with specific emphasis on those studies evaluating their influence on the reduction of heart tissue damage. Conclusion: Introduction of nanoscale drug delivery systems undoubtedly represents nowadays one of the most promising tools for lowering systemic toxicity. Nanoparticles enable to target the therapeutic payload directly towards the tumor tissue, thus leading to the increased accumulation of the drug in the desired tissue and simultaneously protecting surrounding healthy tissues.
ER -
FOJTŮ, Michaela, Jaromír GUMULEC, Tibor STRAČINA, Martina RAUDENSKÁ, Anna SKOTÁKOVÁ, Markéta VACULOVIČOVÁ, Vojtech ADAM, Petr BABULA, Marie NOVÁKOVÁ and Michal MASAŘÍK. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review. \textit{Current Drug Metabolism}. Sharjah: Bentham Science Publishers B.V., 2017, vol.~18, No~3, p.~237-263. ISSN~1389-2002. Available from: https://dx.doi.org/10.2174/1389200218666170105165444.
|
